Metagenomi Common Stock Statistics
Share Statistics
Metagenomi Common Stock has 37.42M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 37.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 253 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 259.37K, so 0.69% of the outstanding shares have been sold short.
| Short Interest | 259.37K |
| Short % of Shares Out | 0.69% |
| Short % of Float | 1.38% |
| Short Ratio (days to cover) | 0.91 |
Valuation Ratios
The PE ratio is -5.67 and the forward PE ratio is -0.76.
| PE Ratio | -5.67 |
| Forward PE | -0.76 |
| PS Ratio | 8.64 |
| Forward PS | 3.7 |
| PB Ratio | -2.85 |
| P/FCF Ratio | -3.82 |
| PEG Ratio | n/a |
Enterprise Valuation
Metagenomi Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.04, with a Debt / Equity ratio of 0.
| Current Ratio | 4.04 |
| Quick Ratio | 4.04 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | -0.16 |
| Cash Flow / Debt | -431.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.5% and return on capital (ROIC) is 101.83%.
| Return on Equity (ROE) | 0.5% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | 101.83% |
| Revenue Per Employee | 189.64K |
| Profits Per Employee | -289.22K |
| Employee Count | 236 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 8.03M |
| Effective Tax Rate | -0.13 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Metagenomi Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 2.14 |
| 200-Day Moving Average | 5.02 |
| Relative Strength Index (RSI) | 75.93 |
| Average Volume (20 Days) | 1.61M |
Income Statement
In the last 12 months, Metagenomi Common Stock had revenue of $44.76M and earned -$68.25M in profits. Earnings per share was $-1.82.
| Revenue | 44.76M |
| Gross Profit | -49.65M |
| Operating Income | -78.49M |
| Net Income | -68.25M |
| EBITDA | -56.02M |
| EBIT | -78.49M |
| Earnings Per Share (EPS) | -1.82 |
Balance Sheet
The company has $140.60M in cash and $48.23M in debt, giving a net cash position of $92.37M.
| Cash & Cash Equivalents | 140.60M |
| Total Debt | 48.23M |
| Net Cash | 92.37M |
| Retained Earnings | -144.94M |
| Total Assets | 358.35M |
| Working Capital | 236.60M |
Cash Flow
In the last 12 months, operating cash flow was -$91.41M and capital expenditures -$9.81M, giving a free cash flow of -$101.22M.
| Operating Cash Flow | -91.41M |
| Capital Expenditures | -9.81M |
| Free Cash Flow | -101.22M |
| FCF Per Share | -2.7 |
Margins
Gross margin is -110.93%, with operating and profit margins of -175.38% and -152.5%.
| Gross Margin | -110.93% |
| Operating Margin | -175.38% |
| Pretax Margin | -134.57% |
| Profit Margin | -152.5% |
| EBITDA Margin | -125.17% |
| EBIT Margin | -175.38% |
| FCF Margin | -226.17% |
Dividends & Yields
MGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -54.98% |
| FCF Yield | -81.59% |
Analyst Forecast
The average price target for MGX is $16, which is 383.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 383.4% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 0.23 |
| Piotroski F-Score | 4 |